This trial is evaluating whether stereotactic body radiotherapy (SBRT) will improve 1 primary outcome and 5 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 6.5 years.
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. Stereotactic Body Radiotherapy (SBRT) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Prostate cancer is a disorder involving malignant tumour formation or malignant proliferation in the peripheral tissues (mucosa or prostatic epithelium) of the prostate gland. Patients are generally diagnosed in their 50s or early 60s and have a very poor outcome, even after radical prostatectomy. It is estimated that in the USA, 21,500 new cases were diagnosed in 2012, making it the eighth most common cancer (after breast, prostate, colorectal, lung, stomach, melanoma and cervical) in this cohort. The global burden of disease for a new prostate cancer diagnosis has been estimated as 14.1 million disability adjusted life years (DALYs)." - Anonymous Online Contributor
"More than 250,000 cases of prostate cancer are diagnosed each year in the United States. Men at high risk for prostate cancer can be identified on the basis of self-report and age." - Anonymous Online Contributor
"More than half (57%) of Americans reported receiving treatment for prostate cancer within the last 12 months. However, only 36% of men reported knowing the side effects or potential risks of the treatment. The reasons for not receiving treatment may be a lack of perceived need, difficulty paying for treatment, limited access to treatment and lack of awareness regarding treatment." - Anonymous Online Contributor
"Current treatment options for prostate cancer include radical prostatic surgery, external beam radiation therapy, and hormone therapy, which may offer symptomatic improvement in half or less than 50% of men. However, these treatments do not provide cure. In the absence of an effective cure for prostate cancer, it would be the only disease in which total remission from symptoms was achieved." - Anonymous Online Contributor
"The genetic and environmental factors are thought to be responsible in a large proportion of cases. Genetic and environmental factors are probably not to blame for a small proportion of cases." - Anonymous Online Contributor
"Symptoms affecting the prostate may include persistent and frequent, painful, or bloody urination, loss of bladder control, or sudden pain or swelling of the penis. Symptoms suggestive of the presence of cancer include persistent headaches or difficulty swallowing, fever, pain or redness in the groin, urinary tract, testicles or prostate, or weight loss.\n\nA physician should recognize any of the signs and symptom patterns that can indicate a diagnosis of prostate cancer – even if the exact cause of the symptoms is not known or if there is a reasonable alternate explanation.\n\nTreating patients with prostate cancer has a significant impact on health care resources." - Anonymous Online Contributor
"The authors conclude that SBRT provides favorable results in patients with primary or metastatic prostate tumors. In addition, it is particularly useful in localized cases. This therapeutic modality is easily administered postoperatively under a sterile technique. A recent meta-analysis has demonstrated an overall survival benefit for SBRT when compared with watchful waiting or radiation alone in localized prostate cancer. Stereotactic body radiation may prove useful for the management of patients with tumors with unfavorable characteristics, such as in patients with a pelvic lymph node involvement or a T-stage of T2a or greater." - Anonymous Online Contributor
"The chances of developing [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) can be defined from the relative risk of developing prostate cancer (RRR of prostate cancer) and the prostate specific antigen (PSA) value. This estimation assumes a constant overall risk of prostate cancer over time as PSA varies." - Anonymous Online Contributor
"Results from a recent clinical trial, there was no improvement in the local control compared with IMRT, but the toxicity was significantly less. SBRT may be considered to be a valid non-hormonal treatment option for men with prostate cancer. However, long-term follow-up is required." - Anonymous Online Contributor
"A variety of research findings related to PSA testing and prostate cancer were reviewed. The most significant research findings are listed below. Bibliography lists research cited by the authors." - Anonymous Online Contributor
"Prostate cancer has a poor prognosis and a high mortality rate. It is possible to identify the specific clinical signs, the risk factors and the most informative treatment of the prostate cancer for a given risk group. This treatment modality may be applied for localized malignant disease or for the whole body. The severity of the prostate cancer, and the risk of treatment failure and post-therapy complications are based on an estimation of the individual clinicopathological features and the clinical course of the disease." - Anonymous Online Contributor
"SBRT for prostate cancer is now a standard of care therapy. A more aggressive approach is associated with improved clinical outcomes and reduced acute toxicity compared with IMRT. This approach may be especially advantageous for patients with high-risk disease, and for those who are not candidates for salvage RT or adjuvant RT following BCT. In the future, a dose escalation strategy combined with a more conservative approach may significantly reduce the need for salvage RT or adjuvant RT for the majority of patients." - Anonymous Online Contributor